Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Mounjaro can slow gallbladder emptying and promote stone formation through rapid weight loss and altered bile composition, leading to upper right abdominal pain or biliary sludge. It offers excellent blood sugar control and weight loss benefits, but recurrent gallbladder issues may prompt discussion of alternative therapies.
There are several factors to consider when deciding whether to continue or switch meds, including your symptom severity, imaging needs, preventive strategies and other treatment options; see below for a detailed breakdown before making any decisions.
Mounjaro (tirzepatide) is a newer medication in the class of GLP-1 receptor agonists, approved to help manage type 2 diabetes and support weight loss. While it offers significant benefits, some users report gallbladder discomfort or pain. Understanding why Mounjaro can cause gallbladder pain—and what you can do about it—helps you make informed decisions about continuing or switching therapy.
Several factors explain the connection between Mounjaro and gallbladder symptoms:
Slowed Gallbladder Emptying
• GLP-1 agonists can reduce gastrointestinal motility, including gallbladder contractions.
• Sluggish emptying means bile stays in the gallbladder longer, increasing the risk of sludge or stones.
Rapid Weight Loss
• Mounjaro often delivers significant weight reduction.
• Quick weight loss is a known trigger for gallstone formation: fat cells release cholesterol into bile, which can crystallize.
Altered Bile Composition
• Changes in hormone signaling may shift the balance of bile acids, cholesterol, and phospholipids.
• An imbalance can increase the likelihood of gallstone development.
Pre-Existing Risk Factors
• Obesity, female sex, age over 40, and family history of gallstones already elevate your baseline risk.
• Adding Mounjaro's effects can tip the scales toward symptomatic gallbladder disease.
Clinical trials and post-marketing surveillance provide insight into incidence rates:
While the percentage may seem low, numbers add up over thousands of users. Being aware of warning signs is key to prompt management.
Symptoms of gallbladder issues can overlap with other digestive complaints. Watch for:
If you experience severe or persistent pain—especially accompanied by fever, chills, or jaundice—seek medical attention immediately.
Deciding whether to continue Mounjaro or switch therapies involves a careful balance of benefits and risks:
If you and your doctor decide to continue Mounjaro, the following strategies may help reduce gallbladder complications:
Slow and Steady Weight Loss
• Aim for gradual reduction (1–2 pounds per week) rather than rapid drops.
• Work with a dietitian on a balanced meal plan.
Dietary Adjustments
• Limit high-fat meals that trigger gallbladder contractions.
• Increase fiber intake (whole grains, fruits, vegetables) to support bile flow.
Regular Monitoring
• Report any abdominal pain promptly.
• Consider periodic liver function tests and ultrasound if recommended.
Hydration and Physical Activity
• Stay well-hydrated to keep bile fluid.
• Regular exercise supports overall gastrointestinal motility.
Medications
• In some cases, ursodeoxycholic acid (UDCA) can be prescribed to reduce stone formation.
• Discuss the risks and benefits of prophylactic therapy with your clinician.
Early detection prevents complications. Contact your healthcare provider if you notice:
If you're unsure whether your symptoms warrant immediate attention, you can use a Medically approved LLM Symptom Checker Chat Bot to help organize your concerns and determine the right next steps before your appointment.
Mounjaro offers compelling benefits for blood sugar control and weight management. However, its impact on gallbladder motility and rapid weight loss can contribute to gallbladder pain or stones in susceptible individuals. Whether to switch medications is a personalized decision that weighs treatment goals against side-effect risks.
Always discuss any new or worsening symptoms with your doctor. If you experience life-threatening signs—such as severe, unrelenting pain with fever or jaundice—seek immediate medical attention. Your healthcare team can guide you toward the safest, most effective regimen for your needs.
(References)
* Zhang X, et al. Cholelithiasis and Cholecystitis Risk with Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Care. 2021 Jul;44(7):e133-e135. DOI: 10.2337/dc21-0428.
* Sun Y, et al. Risk of Gallbladder Disease with Tirzepatide in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne). 2023 Jul 26;14:1222409. DOI: 10.3389/fendo.2023.1222409.
* Heise T, et al. GLP-1 Receptor Agonists and Gallstone Formation: A Narrative Review of Proposed Mechanisms. Adv Ther. 2023 Feb;40(2):494-507. DOI: 10.1007/s12325-022-02381-z.
* Faillie JL, et al. Risk of acute pancreatitis and gallbladder or biliary disease in patients with type 2 diabetes receiving GLP-1 receptor agonists: a population-based cohort study. Diabetes Obes Metab. 2023 Jul;25(7):1987-1996. DOI: 10.1111/dom.15099.
* Zhou X, et al. Tirzepatide and Gallbladder-Related Adverse Events: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Obes Surg. 2024 Jan;34(1):233-241. DOI: 10.1007/s11695-023-06900-5.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.